- Sonoma Pharmaceuticals ( NASDAQ: SNOA ) said it signed an agreement with Daewoong Pharmaceutical to market and distribute Primocyn Skin Solution products in South Korea.
- Under the agreement, Daewoong will have the exclusive right to market, sell and distribute Primocyn Skin Solution products, containing Sonoma's Microcyn technology, in South Korea.
- "Our Microcyn-powered Primocyn products have been sold in South Korea for years, and we look forward to this new partnership with Daewoong Pharmaceutical to open up new sales channels and increase sales of Primocyn in South Korea," said Sonoma CEO Amy Trombly.
- SNOA +17.75% to $1.99 premarket Jan. 31
For further details see:
Sonoma stock surges ~15% on distribution pact with Daewoong in South Korea